Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables
- PMID: 16615041
- DOI: 10.1002/cbf.1325
Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables
Abstract
The balance between matrix metalloproteinases (MMPs) and their physiological tissue inhibitors of matrix metalloproteinases (TIMPs) is crucial in tumour invasion and progression. The aim of this study was to investigate the levels of MMP-9, MMP-3 and TIMP-1 in colorectal cancer (CRC) and to evaluate these proteinases and their inhibitor with respect to clinicopathological variables. Activities of pro- and active MMP-9 were measured in paired tumour and distant normal tissue specimens from 43 patients with CRC using gelatin zymography. ELISA was employed for the determination of MMP-9, MMP-3 and TIMP-1 protein expressions. The activity levels of pro- and active MMP-9 and protein expression levels of MMP-9, MMP-3 and TIMP-1 were higher in tumour tissues than in the corresponding normal tissues; the differences being significant for all (p < 0.05), except TIMP-1. Similarly, active MMP-9/proMMP-9 and the ratio of protein expression level of MMP-9-TIMP-1 were found to be significantly higher in tumour tissues ( p < 0.01). Among all the clinicopathological variables investigated, significant correlations were found between MMP-9 and presence of perineural invasion, MMP-3 and lymph node status, TIMP-1 and tumour differentiation, MMP-9/TIMP-1 ratio and histological types ( p < 0.05). In conclusion, MMP-3 was not as notably increased as MMP-9 in tumour tissues. However, different roles may be attributed to MMP-9 and MMP-3 in CRC development and progression. Additionally, assessment of TIMP-1 in relation to MMPs appeared to be crucial in CRC studies to provide a basis for the re-evaluation of the clinical usefulness of TIMP-1 in colorectal cancer.
(c) 2005 John Wiley & Sons, Ltd.
Similar articles
-
Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.Br J Surg. 2000 Sep;87(9):1215-21. doi: 10.1046/j.1365-2168.2000.01531.x. Br J Surg. 2000. PMID: 10971431
-
Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.Oncol Rep. 2005 Jan;13(1):115-20. Oncol Rep. 2005. PMID: 15583811
-
Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.Arthritis Rheum. 2005 Sep;52(9):2751-60. doi: 10.1002/art.21265. Arthritis Rheum. 2005. PMID: 16142742
-
Matrix metalloproteinases and their inhibitors.Anticancer Res. 1999 Mar-Apr;19(2C):1589-92. Anticancer Res. 1999. PMID: 10365151 Review.
-
Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.Biochimie. 2005 Mar-Apr;87(3-4):377-83. doi: 10.1016/j.biochi.2004.09.022. Biochimie. 2005. PMID: 15781325 Review.
Cited by
-
Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival.PLoS One. 2011;6(9):e25097. doi: 10.1371/journal.pone.0025097. Epub 2011 Sep 26. PLoS One. 2011. PMID: 21966426 Free PMC article.
-
Matrix metalloproteinases: regulators of the tumor microenvironment.Cell. 2010 Apr 2;141(1):52-67. doi: 10.1016/j.cell.2010.03.015. Cell. 2010. PMID: 20371345 Free PMC article. Review.
-
Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance.Oncol Lett. 2011 Nov;2(6):1319-1322. doi: 10.3892/ol.2011.399. Epub 2011 Aug 31. Oncol Lett. 2011. PMID: 22848309 Free PMC article.
-
Expression of Immune-Related and Inflammatory Markers and Their Prognostic Impact in Colorectal Cancer Patients.Int J Mol Sci. 2023 Jul 18;24(14):11579. doi: 10.3390/ijms241411579. Int J Mol Sci. 2023. PMID: 37511338 Free PMC article.
-
Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.BMC Med Genet. 2007 Mar 8;8:10. doi: 10.1186/1471-2350-8-10. BMC Med Genet. 2007. PMID: 17346338 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous